Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
(Posted: 11/04/2010) - The NCI has released initial results from a large-scale test of screening methods to reduce deaths from lung cancer by detecting cancers at relatively early stages. The National Lung Screening Trial, a randomized national trial involving more than 53,000 current and former heavy smokers ages 55 to 74, compared the effects of two screening procedures for lung cancer -- low-dose helical computed tomography (CT) and standard chest X-ray -- on lung cancer mortality and found 20 percent fewer lung cancer deaths among trial participants screened with low-dose helical CT.
Less-Intense Chemo Effective in Children with Intermediate-Risk Neuroblastoma
(Posted: 06/13/2007, Updated: 11/01/2010) - Infants and children with intermediate-risk neuroblastoma who received a less-intensive chemotherapy regimen had three-year overall survival rates as good as those patients in an earlier trial who received treatment that was more intensive and more toxic, according to findings presented at the 2007 ASCO meeting in Chicago.
Hormone Therapy Linked to Modest Increase in Breast Cancer Deaths
(Posted: 10/20/2010) - Women who used combined estrogen and progestin hormone replacement therapy to treat menopausal symptoms during the Women’s Health Initiative (WHI) study had more cases of invasive breast cancer, more lymph-node positive breast cancer, and a slightly higher death rate from breast cancer and other causes than women who received a placebo, researchers reported in an 11-year follow-up report on the study's participants.
Breast Cancer Drug Helps Patients with Gastric Cancer
(Posted: 06/19/2009, Updated: 10/01/2010) - Patients with advanced gastric cancer who received standard chemotherapy plus trastuzumab (Herceptin®) survived several months longer than those who received chemotherapy alone, according to findings presented at the 2009 ASCO meeting in Orlando.
Addition of immunotherapy boosts pediatric cancer survival:
(Posted: 09/29/2010) - Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years. The percentage rose from 46 percent for children receiving a standard therapy to 66 percent for children receiving immunotherapy plus standard therapy, according to the study in the Sept. 30, 2010, New England Journal of Medicine.